The former harbors KRAS mutations and inactivation of STK11, while the latter has co-mutations of NF1 and TP53. However, stratification of these subtypes is mainly based on gene candidates with highly variant expressions across tumor samples without considering the roles of these candidates in tumor malignancy. The gene discussed is TP53; the disease is neoplasm.